AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11195894 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger expression by an unknown politician
Number of subjects: 0
Study 11195894 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger expression by workers in a company
Number of subjects: 0
Study 11195894 — intervention group
Group type: EXPERIMENTAL
Intervention: Angry job candidate description
Number of subjects: 0
Study 11195894 — intervention group
Group type: COMPARATOR
Intervention: Sad job candidate description
Number of subjects: 0
Study 11195894 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger expressions
Number of subjects: 0
Study 9625131 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg mesalazine b.i.d.
Number of subjects: 111
Study 9625131 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg mesalazine u.i.d.
Number of subjects: 111
Study 9625131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 7942050 — intervention group
Group type: EXPERIMENTAL
Intervention: NO concentration at rest
Number of subjects: 27
Study 7942050 — intervention group
Group type: EXPERIMENTAL
Intervention: NO concentration during exercise
Number of subjects: 27
Study 7942050 — intervention group
Group type: EXPERIMENTAL
Intervention: NO concentration in first portion of expired tidal volume
Number of subjects: 27
Study 7942050 — intervention group
Group type: EXPERIMENTAL
Intervention: NO concentration in latter expired portion
Number of subjects: 27
Study 7942050 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measurements of expired NO
Number of subjects: 27
Study 3310626 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g suspension every four hours)
Number of subjects: 100
Study 3310626 — intervention group
Group type: COMPARATOR
Intervention: Antacid (administered every two hours)
Number of subjects: 100
Study 3310626 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 100
Study 3310626 — intervention group
Group type: COMPARATOR
Intervention: Antacid
Number of subjects: 100
Study 31866061 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal approach
Number of subjects: 100
Study 31866061 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of third molars
Number of subjects: 100
Study 28569132 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 52
Study 28569132 — intervention group
Group type: COMPARATOR
Intervention: Common group
Number of subjects: 52
Study 28060214 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-PEMF
Number of subjects: 72
Study 28060214 — intervention group
Group type: COMPARATOR
Intervention: Sham-PEMF
Number of subjects: 72
Study 25526597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification training
Number of subjects: 32
Study 25526597 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 32
Study 23391714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime/avibactam plus metronidazole
Number of subjects: 203
Study 23391714 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 203
Study 19923038 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-30 mg pioglitazone daily (n=21, pioglitazone group)
Number of subjects: 42
Study 19923038 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=21)
Number of subjects: 42
Study 19946230 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (2 g tid for 3 months)
Number of subjects: 68
Study 19946230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 19946230 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 68
Study 17461852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ALCAR 500 mg bid for 14 days followed by oral ALCAR 1000 mg bid for 42 days
Number of subjects: 90
Study 17461852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 17461852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ALCAR
Number of subjects: 90
Study 17461852 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ALCAR
Number of subjects: 90
Study 12928045 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-cueing conditions (informative cue)
Number of subjects: 0
Study 12928045 — intervention group
Group type: COMPARATOR
Intervention: No task-cueing conditions (non-informative cue)
Number of subjects: 0
Study 10877363 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional 1-hour T-piece trial at PSmin
Number of subjects: 36
Study 10877363 — intervention group
Group type: COMPARATOR
Intervention: Extubation directly at PSmin
Number of subjects: 36
Study 10877363 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined patient sample
Number of subjects: 36
Study 9367461 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent live attenuated influenza A virus vaccine (CAV)
Number of subjects: 29
Study 9367461 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza virus vaccine (TVV)
Number of subjects: 29
Study 9367461 — intervention group
Group type: COMPARATOR
Intervention: Trivalent inactivated influenza virus vaccine (TVV) and intranasal placebo
Number of subjects: 29
Study 9367461 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination vaccine regimen (CAV and TVV)
Number of subjects: 29
Study 9367461 — intervention group
Group type: COMPARATOR
Intervention: TVV and intranasal placebo
Number of subjects: 29
Study 1531826 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 120
Study 1531826 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 120
Study 1531826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 3895150 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal instillation of surfactant (3 or 4 mL, prepared from calf lung lavage)
Number of subjects: 72
Study 3895150 — intervention group
Group type: COMPARATOR
Intervention: Control (no surfactant treatment)
Number of subjects: 72
Study 31700099 — intervention group
Group type: EXPERIMENTAL
Intervention: Naked condition
Number of subjects: 27
Study 31700099 — intervention group
Group type: EXPERIMENTAL
Intervention: Type B diapers
Number of subjects: 27
Study 31700099 — intervention group
Group type: COMPARATOR
Intervention: Normal diapers
Number of subjects: 27
Study 28783969 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated platelet-rich plasma
Number of subjects: 58
Study 28783969 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid
Number of subjects: 58
Study 27540182 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 year multiple‐component intervention including youth and adult leader training, peer‐led interactive activities, tobacco cessation camps, enforcement of Tobacco Control Law
Number of subjects: 14
Study 27540182 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 14
Study 25479296 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared-treadmill desk intervention (n = 21)
Number of subjects: 41
Study 25479296 — intervention group
Group type: COMPARATOR
Intervention: Usual working condition control group (n = 20)
Number of subjects: 41
Study 22459543 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mL/kg autologous blood (Group A)
Number of subjects: 44
Study 22459543 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL/kg autologous blood (Group B)
Number of subjects: 44
Study 22459543 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL/kg autologous blood (Group C)
Number of subjects: 44
Study 22459543 — intervention group
Group type: COMPARATOR
Intervention: 1 mL/kg normal saline (Group D)
Number of subjects: 44
Study 20055345 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (15 mg/kg)
Number of subjects: 64
Study 20055345 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 64
Study 18599575 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.1‐mmol/kg)
Number of subjects: 113
Study 18599575 — intervention group
Group type: COMPARATOR
Intervention: Gadodiamide (0.1‐mmol/kg)
Number of subjects: 113
Study 15933967 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative supplemental oxygen (8 L/min for 6 hours)
Number of subjects: 106
Study 15933967 — intervention group
Group type: COMPARATOR
Intervention: Routine care (5 L/min oxygen in PACU, no supplemental oxygen on the ward)
Number of subjects: 106
Study 15933967 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 106
Study 12647922 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive strength training programme
Number of subjects: 17
Study 12647922 — intervention group
Group type: COMPARATOR
Intervention: Control group (no strength training)
Number of subjects: 17
Study 11071800 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab with reduced dose reteplase (5+5 U)
Number of subjects: 299
Study 11071800 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab with reduced dose reteplase (10+5 U)
Number of subjects: 299
Study 11071800 — intervention group
Group type: COMPARATOR
Intervention: standard dose reteplase (10+10 U)
Number of subjects: 299
Study 11071800 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab with reduced dose reteplase (5+5 U or 10+5 U)
Number of subjects: 299
Study 8979645 — intervention group
Group type: COMPARATOR
Intervention: On-ice training (Grp 1)
Number of subjects: 15
Study 8979645 — intervention group
Group type: EXPERIMENTAL
Intervention: On-ice training plus cycle ergometer training (Grp 2)
Number of subjects: 15
Study 1533771 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (5 to 10 mg/day)
Number of subjects: 26
Study 1533771 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 to 200 mg/day)
Number of subjects: 26
Study 3924480 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose TPN (2550 kcal/day)
Number of subjects: 6
Study 3924480 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid TPN (3000 kcal/day)
Number of subjects: 6
Study 3924480 — intervention group
Group type: COMPARATOR
Intervention: Control (255 kcal/day)
Number of subjects: 6
Study 31141081 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized calorie and high protein nutrition therapy (2.0 to 2.2g/kg/day protein)
Number of subjects: 120
Study 31141081 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition care (25kcal/kg/day calories and 1.4 to 1.5g/kg/day protein)
Number of subjects: 120
Study 31141081 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized calorie and high protein nutrition therapy
Number of subjects: 120
Study 31141081 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition care
Number of subjects: 120
Study 31141081 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 30543657 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanofi Pasteur recombinant, live, attenuated, tetravalent vaccine (CYD‐TDV)
Number of subjects: 0
Study 30543657 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 26577417 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 466
Study 26577417 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 466
Study 25297613 — intervention group
Group type: COMPARATOR
Intervention: Dietary fiber materials (DFMs) including polydextrose, partially hydrolysed guar gum, resistant maltodextrin, partially hydrolysed alginate, glucomannan, heat‐moisture treatment, high‐amylose cornstarch, cellulose
Number of subjects: 0
Study 22314538 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-sulfadoxine-pyrimethamine (AS-SP)
Number of subjects: 157
Study 22314538 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AM-LF)
Number of subjects: 157
Study 22314538 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine (AS-MQ)
Number of subjects: 157
Study 20530317 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg/d
Number of subjects: 427
Study 20530317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study 18057563 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation framework composed of ten quality criteria
Number of subjects: 40
Study 18057563 — intervention group
Group type: COMPARATOR
Intervention: No evaluation framework
Number of subjects: 40
Study 15651575 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic electrodes after degradation
Number of subjects: 12
Study 15651575 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased electrode impedance
Number of subjects: 12
Study 11544433 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 10
Study 11544433 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose (placebo group)
Number of subjects: 10
Study 9164520 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Injection Sclerotherapy (EIS)
Number of subjects: 61
Study 9164520 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy (Endoscopic Variceal Ligation + EIS)
Number of subjects: 61
Study 7970945 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhesus-human reassortant tetravalent oral rotavirus vaccine (4 x 10^4 plaque-forming units)
Number of subjects: 187
Study 7970945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 3556051 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol
Number of subjects: 19
Study 3556051 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol from metered-dose inhaler (MDI)
Number of subjects: 19
Study 3556051 — intervention group
Group type: EXPERIMENTAL
Intervention: Both delivery systems (nebulizer and MDI)
Number of subjects: 19
Study 1978667 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (20 mg)
Number of subjects: 20
Study 1978667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1125653 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma immunoreactive beta‐melanocyte stimulating hormone (beta‐MSH) concentrations
Number of subjects: 0
Study 1125653 — intervention group
Group type: COMPARATOR
Intervention: Severity of renal failure
Number of subjects: 0
Study 1125653 — intervention group
Group type: COMPARATOR
Intervention: Degree of pigmentation
Number of subjects: 0
Study 31784217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Number of subjects: 0
Study 31784217 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label ivacaftor
Number of subjects: 0
Study 31784217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31726714 — intervention group
Group type: EXPERIMENTAL
Intervention: Winter ice-cream intake
Number of subjects: 136
Study 31726714 — intervention group
Group type: EXPERIMENTAL
Intervention: Chickpeas intake
Number of subjects: 136
Study 31726714 — intervention group
Group type: EXPERIMENTAL
Intervention: Not industrial aged-cheeses type
Number of subjects: 136
Study 31726714 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit meat
Number of subjects: 136
Study 31726714 — intervention group
Group type: EXPERIMENTAL
Intervention: Industrial type aged cheeses
Number of subjects: 136
Study 31726714 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-based desserts (no winter ice cream)
Number of subjects: 136
Study 31726714 — intervention group
Group type: EXPERIMENTAL
Intervention: Fats
Number of subjects: 136
Study 26711194 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-down-tilt sleeping hypokinetic subjects (HDTSHS)
Number of subjects: 40
Study 26711194 — intervention group
Group type: COMPARATOR
Intervention: Head-down-tilt sleeping control subjects (HDTSCS)
Number of subjects: 40
Study 26711194 — intervention group
Group type: COMPARATOR
Intervention: Hypokinetic subjects (HKS)
Number of subjects: 40
Study 26711194 — intervention group
Group type: COMPARATOR
Intervention: Active control subjects (ACS)
Number of subjects: 40
Study 26004031 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week program of enhanced physiotherapy and structured exercise (PEPSE) and essential amino acid supplement drink (glutamine and essential amino acid mixture [GEAA])
Number of subjects: 93
Study 26004031 — intervention group
Group type: EXPERIMENTAL
Intervention: GEAA supplement with PEPSE
Number of subjects: 93
Study 26004031 — intervention group
Group type: COMPARATOR
Intervention: Control supplement/PEPSE
Number of subjects: 93
Study 26004031 — intervention group
Group type: EXPERIMENTAL
Intervention: GEAA supplement/PEPSE
Number of subjects: 93
Study 24229738 — intervention group
Group type: EXPERIMENTAL
Intervention: GeneSight pharmacogenomic-informed treatment (n=26)
Number of subjects: 51
Study 24229738 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) (n=25)
Number of subjects: 51
Study 21714710 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic SFG (Nulecit)
Number of subjects: 240
Study 21714710 — intervention group
Group type: COMPARATOR
Intervention: Branded SFG (Ferrlecit)
Number of subjects: 240
Study 19046471 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic septoplasty
Number of subjects: 80
Study 19046471 — intervention group
Group type: COMPARATOR
Intervention: Conventional septoplasty
Number of subjects: 80
Study 19046471 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 16913263 — intervention group
Group type: EXPERIMENTAL
Intervention: R112
Number of subjects: 20
Study 16913263 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 20
Study 15000796 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care integration with case management
Number of subjects: 0
Study 15000796 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 11323501 — intervention group
Group type: EXPERIMENTAL
Intervention: c-erbB-2 expression
Number of subjects: 311
Study 11323501 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 expression
Number of subjects: 311
Study 11323501 — intervention group
Group type: EXPERIMENTAL
Intervention: Coexpression of c-erbB-2 and p53
Number of subjects: 311
Study 11323501 — intervention group
Group type: EXPERIMENTAL
Intervention: T stage
Number of subjects: 311
Study 11323501 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal status
Number of subjects: 311
Study 9416313 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate levels in peritumoral edema
Number of subjects: 18
Study 9416313 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate levels in peritumoral edematous tissue
Number of subjects: 18
Study 8487513 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug and alcohol abuse prenatal care health education program
Number of subjects: 212
Study 8487513 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 212
Study 3324648 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (40 or 60 mg)
Number of subjects: 96
Study 3324648 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline (75 or 150 mg)
Number of subjects: 96
Study 3324648 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 96
Study 3324648 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline
Number of subjects: 96
Study 29273390 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 643
Study 29273390 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 643
Study 27064499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 28
Study 27064499 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 28
Study 27064499 — intervention group
Group type: COMPARATOR
Intervention: DAPT alone (Control)
Number of subjects: 28
Study 24679203 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryan Cervical Disc System
Number of subjects: 50
Study 24679203 — intervention group
Group type: EXPERIMENTAL
Intervention: ACCEL system
Number of subjects: 50
Study 24679203 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study 23747582 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Mindfulness Based Stress Reduction (MBSR)
Number of subjects: 71
Study 23747582 — intervention group
Group type: COMPARATOR
Intervention: Group Cognitive Behavioral Therapy (CBT)
Number of subjects: 71
Study 20978447 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/kg bevacizumab
Number of subjects: 304
Study 20978447 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg bevacizumab
Number of subjects: 304
Study 20978447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 19055885 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional resin sealant
Number of subjects: 45
Study 19055885 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer (RMGI)
Number of subjects: 45
Study 19055885 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable composite
Number of subjects: 45
Study 19055885 — intervention group
Group type: COMPARATOR
Intervention: Control group (RMGI)
Number of subjects: 45
Study 16322492 — intervention group
Group type: EXPERIMENTAL
Intervention: FNS‐IM (Functional Neuromuscular Stimulation using intramuscular electrodes)
Number of subjects: 32
Study 16322492 — intervention group
Group type: COMPARATOR
Intervention: No‐FNS (No Functional Neuromuscular Stimulation)
Number of subjects: 32
Study 14653434 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcortical hyperintensity (SH) volume
Number of subjects: 0
Study 14653434 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain volume (WBV)
Number of subjects: 0
Study 14653434 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcortical hyperintensity (SH) volume after 12 months
Number of subjects: 0
Study 14653434 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain volume (WBV) after 12 months
Number of subjects: 0
Study 11286465 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol 160 mg day(-1)
Number of subjects: 45
Study 11286465 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no treatment)
Number of subjects: 45
Study 9240185 — intervention group
Group type: EXPERIMENTAL
Intervention: tamsulosin (0.2 mg/day)
Number of subjects: 128
Study 9240185 — intervention group
Group type: EXPERIMENTAL
Intervention: allylestrenol (50 mg/day)
Number of subjects: 128
Study 8214993 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin, 80 mg/day
Number of subjects: 270